

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (currently amended) A method of treatment for a mammal, with advanced or large tumor burdens, comprising the administration to said mammal of a T-cell co-stimulatory cell adhesion molecule (CAM) in conjunction with a tumor growth-restricting agent, either of which alone would be ineffective in ~~eradicating~~ treating an advanced or large tumor burden, wherein said CAM is B7.1 and wherein said tumor growth restricting agent is DMXAA.

2. (currently amended) A method of treating a patient with cancer which comprises the step of administering to said patient a CAM and a tumor growth-restricting agent in amounts which are together effective to ~~eradicate~~ treat any advanced or large tumors present, wherein said CAM is B7.1 and wherein said tumor growth restricting agent is DMXAA.

3. (currently amended) A method of potentiating the activity of a CAM against tumors present in a patient suffering from cancer which comprises the step of administering to said patient treated with said CAM an amount of a tumor growth-restricting agent, which is effective, in combination with said CAM to ~~eradicate~~ treat any advanced or large tumors present in said patient, wherein said CAM is B7.1 and wherein said tumor growth restricting agent is DMXAA.

4. (currently amended) A method of potentiating the activity of a tumor growth restricting agent against tumors present in a patient suffering from cancer which comprises the step of pre-administering to a patient to be treated with said tumor growth-restricting agent an amount of CAM which, upon subsequent administration of said tumor growth restricting agent, acts in combination with said tumor growth restricting agent to ~~eradicate~~ treat an advanced or large tumors present, wherein said CAM is B7.1 and wherein said tumor growth restricting agent is DMXAA.

5-9. (canceled).

10. (withdrawn) A method as claimed in claim 1, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).

11. (withdrawn) A method as claimed in claim 10, wherein the wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

12. (previously presented) A method as claimed in claim 1, wherein the CAM is administered prior to the administration of the tumor growth-restricting agent.

13. (previously presented) A method as claimed in claim 12, wherein the CAM is administered from 12 to 48 hours prior to the administration of the tumor growth-restricting agent.

14. (original) A method as claimed in claim 1, wherein the method further includes the administration of an additional tumor growth-restricting agent.

15. (withdrawn) A method as claimed in claim 14, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF-1).

16-17. (canceled).

18. (withdrawn) A method as claimed in claim 2, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).

19. (withdrawn) A method as claimed in claim 18, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

20. (previously presented) A method as claimed in claim 2, wherein the CAM is administered prior to the administration of the tumor growth-restricting agent.

21. (previously presented) A method as claimed in claim 20, wherein the CAM is administered from 12 to 48 hours prior to the administration of the tumor growth-restricting agent.

22. (original) A method as claimed in claim 2, wherein the method further includes the administration of an additional tumor growth-restricting agent.

23. (withdrawn) A method as claimed in claim 22, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF- 1).

24-25. (canceled).

26. (withdrawn) A method as claimed in claim 3, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).

27. (withdrawn) A method as claimed in claim 26, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

28. (previously presented) A method as claimed in 3, wherein the CAM is administered prior to the administration of the tumor growth-restricting agent.

29. (previously presented) A method as claimed in claim 28, wherein the CAM is administered from 12 to 48 hours prior to the administration of the tumor growth-restricting agent.

30. (original) A method as claimed in claim 3, wherein the method further includes the administration of an additional tumor growth-restricting agent.

31. (withdrawn) A method as claimed in claim 30, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF-1).

32-33. (canceled).

34. (withdrawn) A method as claimed in claim 4, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).

35. (withdrawn) A method as claimed in claim 34, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

36. (previously presented) A method as claimed in claim 4, wherein the CAM is administered prior to the administration of the tumor growth-restricting agent.

37. (previously presented) A method as claimed in claim 36, wherein the CAM is administered from 12 to 48 hours prior to the administration of the tumor growth-restricting agent.

38. (original) A method as claimed in claim 4, wherein the method further includes the administration of an additional tumor growth-restricting agent.

39. (withdrawn) A method as claimed in claim 38, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF- 1).

40-55. (canceled).

[REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK]